Re­gen­eron and Mam­moth strike $100M deal to pair tiny CRISPR ed­i­tors with new de­liv­ery idea

Re­gen­eron is ex­pand­ing its ge­net­ic med­i­cine ef­forts and will work with Cal­i­for­nia start­up Mam­moth Bio­sciences on gene-edit­ing pro­grams reach­ing parts of the hu­man body be­yond the liv­er, the com­pa­nies an­nounced Thurs­day.

While CRISPR/Cas9 gene-edit­ing tech­nol­o­gy has won a No­bel Prize, bio­phar­ma com­pa­nies have strug­gled to turn the tool in­to ther­a­pies that can reach many of the body’s tis­sues and or­gans. In­stead, drug de­vel­op­ers have crowd­ed in­to dis­ease tar­gets in the liv­er, the clear­ing­house or­gan where de­liv­ery sys­tems like lipid nanopar­ti­cles or vi­ral vec­tors typ­i­cal­ly wind up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER